Answers are grounded in this paper and cite their sources.
Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.
No takes yet. Share an insight, caveat, or question.
Drucker et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: